CN110446496A - 用于治疗糖尿病的系统、组合物和方法 - Google Patents

用于治疗糖尿病的系统、组合物和方法 Download PDF

Info

Publication number
CN110446496A
CN110446496A CN201880022823.0A CN201880022823A CN110446496A CN 110446496 A CN110446496 A CN 110446496A CN 201880022823 A CN201880022823 A CN 201880022823A CN 110446496 A CN110446496 A CN 110446496A
Authority
CN
China
Prior art keywords
insulin
glucagon
molar ratio
formulation
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880022823.0A
Other languages
English (en)
Chinese (zh)
Inventor
A.彻林顿
D.马格斯
S.高希
C.A.罗德斯
J.林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to CN202311408454.8A priority Critical patent/CN117653715A/zh
Publication of CN110446496A publication Critical patent/CN110446496A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880022823.0A 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法 Pending CN110446496A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311408454.8A CN117653715A (zh) 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454613P 2017-02-03 2017-02-03
US62/454613 2017-02-03
PCT/US2018/016647 WO2018144867A1 (en) 2017-02-03 2018-02-02 Systems, compositions and methods for treating diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311408454.8A Division CN117653715A (zh) 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法

Publications (1)

Publication Number Publication Date
CN110446496A true CN110446496A (zh) 2019-11-12

Family

ID=63041127

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880022823.0A Pending CN110446496A (zh) 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法
CN202311408454.8A Pending CN117653715A (zh) 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311408454.8A Pending CN117653715A (zh) 2017-02-03 2018-02-02 用于治疗糖尿病的系统、组合物和方法

Country Status (6)

Country Link
US (3) US11357829B2 (enExample)
EP (2) EP3576748B1 (enExample)
JP (1) JP7133229B2 (enExample)
CN (2) CN110446496A (enExample)
ES (2) ES2944544T3 (enExample)
WO (1) WO2018144867A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115811985A (zh) * 2020-07-07 2023-03-17 加利福尼亚大学董事会 用于递送胰岛素和胰高血糖素的治疗性混合微针贴片

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617832B2 (en) 2016-08-17 2023-04-04 International Business Machines Corporation Portal system-based bionic pancreas
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
FI4069278T3 (fi) * 2019-12-06 2025-07-16 Dr Mary Morris & Ass Llc Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
WO2022173807A2 (en) 2021-02-09 2022-08-18 The Trustees Of Indiana University Conformationally constrained glucagon analogues and their use in glucagon-single chain insulin fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20060014670A1 (en) * 2002-12-27 2006-01-19 Green Daniel T Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
ZA200700708B (en) * 2004-06-29 2009-03-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
WO2012122535A2 (en) * 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6538645B2 (ja) * 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
US9381292B2 (en) * 2014-07-24 2016-07-05 Kamal Ahmed ALJOHANI Diabetes regulator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20060014670A1 (en) * 2002-12-27 2006-01-19 Green Daniel T Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115811985A (zh) * 2020-07-07 2023-03-17 加利福尼亚大学董事会 用于递送胰岛素和胰高血糖素的治疗性混合微针贴片

Also Published As

Publication number Publication date
US20250057923A1 (en) 2025-02-20
WO2018144867A1 (en) 2018-08-09
ES2944544T3 (es) 2023-06-22
JP2020505429A (ja) 2020-02-20
EP3576748A1 (en) 2019-12-11
US11357829B2 (en) 2022-06-14
US20200230211A1 (en) 2020-07-23
EP3576748B1 (en) 2023-04-05
EP4233876A1 (en) 2023-08-30
JP7133229B2 (ja) 2022-09-08
ES3040364T3 (en) 2025-10-30
US20220273771A1 (en) 2022-09-01
EP3576748A4 (en) 2020-11-04
CN117653715A (zh) 2024-03-08
EP4233876B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
JP7133229B2 (ja) 糖尿病を治療するためのシステム、組成物および方法
Heise The future of insulin therapy
Zinman et al. Insulin lispro in CSII: results of a double-blind crossover study
Heise et al. Insulin stacking versus therapeutic accumulation: understanding the differences
Kerr et al. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review
AU2016202156B2 (en) Controlled release peptide formulations
Senior et al. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective
US20100069292A1 (en) Insulin with a basal release profile
WO2013177565A1 (en) Insulin-pramlintide compositions and methods for making and using them
Van Dijk et al. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia
KR20050086948A (ko) 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
WO2019147718A1 (en) Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
US20240016898A1 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
Heinemann et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin
Umpierrez et al. Concentrated insulins: clinical update of therapeutic options
WO2016069409A1 (en) Parenteral glucagon formulations
HK40099895B (en) Systems, compositions and methods for treating diabetes
HK40099895A (en) Systems, compositions and methods for treating diabetes
US20200147306A1 (en) Methods for treating congenital hyperinsulinism
US20230293639A1 (en) Systems, devices, compositions, and methods for treating diabetes
Leelarathna et al. Dual-hormone Automated Insulin Delivery
Nelson Use of Insulin, Pumps and Continuous Glucose Monitoring
JP2024528457A (ja) 治療方法およびデバイス
Sharma Emerging Injectable Therapies in Type 2 Diabetes Mellitus
Dills New aspects of insulin therapy in Type 1 and Type 2 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191112